Products for Research Use Only

(2R) -Mitiglinide-d5 (calcium)

CAT: 0804-HY-B0682S1-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-B0682S1-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
(2R) -Mitiglinide-d5 (calcium) is deuterium labeled Mitiglinide. Mitiglinide (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel) . Mitiglinide can be used for the research of type 2 diabetes[1][2].
UNSPSC
12352005
Target
Isotope-Labeled Compounds; Potassium Channel
Type
Isotope-Labeled Compounds
Related Pathways
Membrane Transporter/Ion Channel; Others
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease
Solubility
10 mM in DMSO
Smiles
O=C(N1C[C@@](CCCC2)([H])[C@@]2([H])C1)C[C@H](C([O-])=O)CC3=C([2H])C([2H])=C([2H])C([2H])=C3[2H].[Ca+2].[1/2]
Molecular Formula
C19H19D5NO3.1/2Ca
Molecular Weight
339.48
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Kiyoshi Ichikawa, et al. Effect of KAD-1229, a novel hypoglycaemic agent, on plasma glucose levels after meal load in type 2 diabetic rats. Clin Exp Pharmacol Physiol. May-Jun 2002;29 (5-6) :423-7.|[3]Y Sunaga, et al. The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide. Eur J Pharmacol. 2001 Nov 9;431 (1) :119-25.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported